To the full analysis
Buyback calculator for Avita Medical
Avita Medical stock: key metrics
RCELAvita Medical had an operating margin of −59.4% and a return on invested capital (ROIC) of −69.8% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | −46.2% | −1,054.4% | −1,747.6% |
| 2007 | 59.1% | −402.4% | −968.8% |
| 2008 | 88.0% | −250.8% | −236.2% |
| 2009 | 68.7% | −111.0% | −211.3% |
| 2010 | 70.8% | −164.4% | −62.5% |
| 2011 | 71.6% | −209.7% | −218.6% |
| 2012 | 76.0% | −306.7% | −287.5% |
| 2013 | 75.0% | −254.2% | −191.8% |
| 2014 | 91.8% | −887.7% | −1,037.0% |
| 2015 | 59.9% | −1,025.1% | −1,025.1% |
| 2016 | 57.2% | −1,073.2% | −975.0% |
| 2017 | 41.2% | −812.0% | −1,370.8% |
| 2018 | 76.8% | −466.4% | −458.6% |
| 2019 | 79.2% | −299.2% | −294.7% |
| 2020 | 79.6% | −90.8% | −90.9% |
| 2022 | 82.4% | −79.9% | −77.5% |
| 2023 | 84.5% | −85.1% | −70.6% |
| 2024 | 85.8% | −88.1% | −96.3% |
| 2025 | 82.1% | −59.4% | −67.8% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −100.0% | −55.5% | −100.0% |
| 2007 | −90.0% | −29.6% | −75.2% |
| 2008 | −59.7% | −95.1% | −52.2% |
| 2009 | −100.0% | −91.6% | −63.7% |
| 2010 | −12.3% | −33.8% | −11.2% |
| 2011 | −88.7% | −45.5% | −70.9% |
| 2012 | −77.4% | −71.4% | −62.7% |
| 2013 | −93.1% | −65.5% | −70.4% |
| 2014 | −100.0% | no data | −100.0% |
| 2015 | −100.0% | no data | −100.0% |
| 2016 | −100.0% | no data | −100.0% |
| 2017 | −90.6% | −62.9% | −74.8% |
| 2018 | −100.0% | no data | −100.0% |
| 2019 | −58.1% | −70.2% | −51.0% |
| 2020 | −23.0% | −21.7% | −21.2% |
| 2022 | −31.5% | −22.4% | −27.1% |
| 2023 | −72.1% | −36.2% | −31.7% |
| 2024 | −100.0% | −56.6% | −77.6% |
| 2025 | 200.0% | −69.8% | −86.2% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2023)
- Valuation signal Fairly valued since 13 Nov 2026, previously Overvalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.